- Company
- Could Lilly Retatrutide be a game-changer for obesity drug?
- by Nho, Byung Chul Aug 14, 2023 05:21am
- Attention is focusing on whether Eli Lilly can commercialize another blockbuster drug in the global obesity drug market worth 13 trillion won by entering phase 3 clinical trials for new drug candidates, Orforglipron and Retatrutide. According to related industries, the Ministry of Food and Drug Safety approved the phase 3 clinical trial to c
- Company
- Imbruvica passed the drug reimbursement evaluation committee
- by Eo, Yun-Ho Aug 11, 2023 05:36am
- Imbruvica, a blood cancer treatment, has made progress in discussing the expansion of insurance benefits about a year after passing the cancer disease review committee. According to the related industry, Imbruvica's first-line indication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) passed the HIRA drug reimburse
- Company
- Will Darzalex be reimb as 2nd-line treatment for MM?
- by Eo, Yun-Ho Aug 11, 2023 05:35am
- Whether progress will be made on the discussions on extending reimbursement of the multiple myeloma treatment ‘Darzalex’ as second-line treatment is gaining attention. According to industry sources, Janssen Korea is reattempting to apply for reimbursement of its 'Darzalex (daratumumab)' to be reviewed by the Health Insurance Review and
- Company
- Lotte Biologics advances CDMO Biz with Roche Diagnostics
- by Jung, Sae-Im Aug 10, 2023 05:33am
- On the 9th, Lotte Biologics announced that it had recently signed a Memorandum of Understanding (MOU) with Roche Diagnostics, the diagnostic division of the Roche Group, to advance the productivity and quality of its Contract Development and Manufacturing Organization (CDMO) business. The MOU, which was signed at Penzberg, where Roche Dia
- Company
- Generic drugs occupy over 70% of tamsulosin market
- by Kim, Jin-Gu Aug 10, 2023 05:33am
- The share of generic drugs in the market for prostatic hyperplasia treatments that contain tamsulosin exceeded 70%. This is interpreted as an effect of the rapid rise in generic sales while the prescription performance of original products slowed down. One variable in this market is impurities. At the end of June, impurities were detected i
- Company
- Patent dispute over Entresto's patents continue
- by Kim, Jin-Gu Aug 10, 2023 05:33am
- The patent dispute over ‘Entresto (sacubitril/valsartan),’ a chronic heart failure treatment with an annual prescription of more than KRW 40 billion, has been ongoing for over 2 years now. Novartis, the company that owns the original drug, is actively pursuing a defense strategy against generic companies' patent challenges. Novartis app
- Company
- Chong Kun Dang/Cell Biotech, big match in the MicrobiomeCDMO
- by Nho, Byung Chul Aug 8, 2023 05:30am
- It is expected that CKD Bio and Cell Biotech will compete to expand the related market in the microbiome drug CDMO (Contract Development Manufacturing) field. According to the Korea Institute of Science and Technology Information, the global market for human microbiome is expected to reach 1,743.8 billion won in 2029 with a rapid average annu
- Company
- Union Korea Pharm agrees to export 8 drugs to Jurabek
- by Lee, Seok-Jun Aug 8, 2023 05:30am
- Union Korea Pharm signed an agreement to export 8 types of drugs with its Uzbekistan partner, Jurabek Laboratories. According to the company on the 7th, the 8 export items include the company’s representative antibiotics and injections such as Atrasen Tab, Serokfen Tab, Uni-Minoxidil Tab, Atorvan Tab, Kefodon Inj, and Amikacin Inj. Th
- Company
- Immuno-anticancer drugs have brought us closer
- by Jung, Sae-Im Aug 8, 2023 05:30am
- Immuno-anticancer agents are active in early lung cancer. Following 'Opdivo (Nivolumab),' which obtained the indication for adjuvant therapy before surgery for the first time, 'Keytruda (Pembrolizumab)' is also seeking to expand its scope as adjuvant therapy before and after surgery. The data shown by immuno-anticancer drugs in early lung
- Company
- ‘Competitors eye Eylea due to its many benefits’
- by Jung, Sae-Im Aug 8, 2023 05:30am
- The fact that many companies are concentrating on the development of Eylea biosimilars is proof of the many advantages owned by Eylea. We plan to continue to make known the strengths of Eylea while developing new products to continue to deliver on our patient and HCP-centric treatment strategy.” Sangok Suh, Head of the Specialty Medicine bus
